Data show fading protection from Pfizer jab after six months

29 July 2021
biontech_vaccine_large

On the same day that New York’s Pfizer (NYSE: PFE) released  stellar second-quarter financials, the company also made public less encouraging news on the vaccine front.

In an important ongoing study testing the mRNA-based jab on over 44,000 people, efficacy appeared to drop by around 6% every two months, reaching 84% after half a year.

Dubbed BNT162b2 and known as Comirnaty in Europe, the long-term impact of the vaccine is being tested on people aged 12 and over, given two injections of either the vaccine or a placebo, with a three week interval.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology